Replimune Group Q3 EPS Forecast Boosted by HC Wainwright

Replimune Group, Inc. (NASDAQ:REPL) – Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Replimune Group in a report released on Tuesday, November 12th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.73) per share for the quarter, up from their prior forecast of ($0.79). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

Several other research analysts have also recently issued reports on REPL. JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm assumed coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Down 5.3 %

REPL opened at $10.80 on Friday. The stock’s 50 day moving average price is $11.46 and its 200 day moving average price is $9.57. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. The stock has a market cap of $738.94 million, a P/E ratio of -3.54 and a beta of 1.19. Replimune Group has a 12 month low of $4.92 and a 12 month high of $12.97.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in shares of Replimune Group during the 1st quarter valued at about $927,000. Jacobs Levy Equity Management Inc. acquired a new stake in Replimune Group during the first quarter valued at approximately $1,088,000. Price T Rowe Associates Inc. MD lifted its stake in Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares during the last quarter. Millennium Management LLC boosted its holdings in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.